Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma Clinical Trial

Official title: Renal Tumors Classification, Biology, and Banking Study

Status Recruiting

Clinical Trial Summary

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Classify patients with renal tumors by histological categorization, surgico-pathological stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity for chromosomes 1p and 16q, to define eligibility for a series of therapeutic studies. (As of Amendment 8, this aim is limited to patients with institutionally classified Stage I to IV focal or diffuse anaplasia identified at initial biopsy or primary nephrectomy OR at delayed nephrectomy/second biopsy.) II. To maintain a biological samples bank to make specimens available to scientists to evaluate additional potential biological prognostic variables and for the conduct of other research by scientists. SECONDARY OBJECTIVES: I. To monitor outcome for those patients who are not eligible for a subsequent therapeutic study. II. To describe whether the pulmonary tumor burden correlates with outcome in Stage IV patients.(Completed as of Amendment 7) III. To describe the sensitivity and specificity of abdominal computed tomography (CT) by comparison with surgical and pathologic findings for identification of local tumor spread beyond the renal capsule to adjacent muscle and organs, lymph node involvement at the renal hilum and in the retroperitoneum, preoperative tumor rupture and metastases to the liver. (Completed as of Amendment 7) IV. To compare the sensitivity and specificity of preoperative abdominal CT and MRI for the identification and differentiation of nephrogenic rests and Wilms tumor in children with multiple renal lesions. (Completed as of Amendment 7) V. To correlate the method of conception (natural versus assisted reproductive technology) with the development of Wilms tumor. (Completed as of Amendment 7) VI. To evaluate the frequency of integrase interactor 1 (INI1) mutations in renal and extrarenal malignant rhabdoid tumor of the kidney and to determine the incidence of germline and inherited versus somatic mutations to facilitate clinical correlations on the companion study AREN0321. (Completed as of Amendment 7) OUTLINE: Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014) Patients are followed up periodically for 5 years. ;

Related Conditions & MeSH terms

• Adenoma
• Adult Cystic Nephroma
• Anaplastic Kidney Wilms Tumor
• Angiolipoma
• Carcinoma
• Carcinoma, Renal Cell
• Cellular Congenital Mesoblastic Nephroma
• Classic Congenital Mesoblastic Nephroma
• Clear Cell Sarcoma of the Kidney
• Congenital Mesoblastic Nephroma
• Cystic Partially Differentiated Kidney Nephroblastoma
• Diffuse Hyperplastic Perilobar Nephroblastomatosis
• Extrarenal Rhabdoid Tumor
• Kidney Medullary Carcinoma
• Kidney Neoplasm
• Kidney Neoplasms
• Kidney Oncocytoma
• Kidney Wilms Tumor
• Metanephric Adenofibroma
• Metanephric Adenoma
• Metanephric Stromal Tumor
• Metanephric Tumor
• Mixed Congenital Mesoblastic Nephroma
• Neoplasms
• Ossifying Renal Tumor of Infancy
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma
• Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
• Rhabdoid Tumor
• Rhabdoid Tumor of the Kidney
• Sarcoma, Clear Cell
• Wilms Tumor

• NCT number: NCT00898365
• Study type: Observational
• Source: Children's Oncology Group
• Status: Recruiting
• Start date: February 27, 2006